Ultomiris demonstrated sustained improvements in functional activities and quality of life in adults with generalised myasthenia gravis through 60 weeks
Analysis of Phase III CHAMPION-MG trial open-label extension adds to growing body of safety and efficacy data for Ultomiris in generalised myasthenia gravis. Patients who transitioned from placebo to Ultomiris showed rapid and sustained response, reinforcing clinical benefit of C5 inhibition.New, prolonged follow-up results from the Phase III CHAMPION-MG trial open-label extension (OLE) showed that Ultomiris (ravulizumab-cwvz) demonstrated long-term efficacy in adults with anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis (gMG), with improvements in